Together, these data position coumarin–pyrazole carbodithioates as versatile, chemically stable leads for NSCLC discovery campaigns, combining CDK2 engagement with tunable potency and properties amenable to optimization [53,54]. Here, CDK2 is linked to non-small cell lung carcinoma.